Hepatitis B virus (HBV) encoded x antigen (HBxAg) is a trans-activating protein that contributes to the development of hepatocellular carcinoma (HCC) by the up- or down-regulated expression of selected hepatocellular genes. To identify some of these genes, HBxAg or vector were introduced into the human hepatoblastoma cell line, HepG2. Differentially expressed genes were identified by microarray analysis and by PowerBlot (SDS/PAGE followed by western blotting). Both assays showed decreased E-cadherin and increased expression of b-catenin and several b-catenin target genes in HBxAg [+] compared to [-] cells. In the livers of HBV carriers, there was an inverse relationship between HBxAg staining and E-cadherin and co- staining between HBxAg and b-catenin, suggesting that HBxAg contributes to hepatocellular transformation by altering the b-catenin signaling pathway. Hence, the objective of this work is to elucidate the mechanisms whereby HBxAg stabilizes b-catenin and thereby stimulates signaling, and to determine the contribution of these mechanisms to HBxAg mediated transformation. Accordingly, experiments will test the hypothesis that the accumulation/activation of b-catenin in HBxAg positive cells results from HBxAg trans-activation of the b-catenin gene, from HBxAg inactivation of glycogen synthase kinase 3b (GSKSp), from the HBxAg down-regulation of E-cadherin, and/or from the HBxAg inhibition of b-catenin degradation in the proteasome (Aim 1). Additional experiments will test whether the HBxAg stabilization of b-catenin contributes to the pathogenesis of HCC (Aim 2). These experiments will establish the extent to which up-regulated b-catenin signaling underlies the pleiotropic properties whereby HBxAg contributes to HCC development on the molecular level, and the corresponding mechanism(s) whereby this occurs. Given that wild type b-catenin is up-regulated in the majority of HBV associated HCCs, elucidation of the underlying mechanism(s) will identify critical pathways that will be targeted for chemoprevention of HCC and for therapeutic intervention in tumor bearing patients. The results from this research would also provide therapeutic targets for the application of existing drugs (against b-catenin effectors) in patients with HCC. In doing so, the proposed work is expected to promote the development of multiple public health benefits for HBV infected carriers with chronic liver disease and HCC. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA104025-02
Application #
7176228
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2006-02-06
Project End
2007-09-04
Budget Start
2007-02-01
Budget End
2007-09-04
Support Year
2
Fiscal Year
2007
Total Cost
$267,147
Indirect Cost
Name
Thomas Jefferson University
Department
Pathology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Feitelson, Mark A; Bonamassa, Barbara; Arzumanyan, Alla (2014) The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease. Expert Opin Ther Targets 18:293-306
Mesri, Enrique A; Feitelson, Mark A; Munger, Karl (2014) Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15:266-82
Arzumanyan, Alla; Reis, Helena M G P V; Feitelson, Mark A (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13:123-35
Arzumanyan, A; Friedman, T; Kotei, E et al. (2012) Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 31:563-72
Yuan, Ke; Lian, Zhaorui; Sun, Bill et al. (2012) Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One 7:e35331
Schinazi, Raymond F; Bassit, Leda; Clayton, Marcia M et al. (2012) Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother 56:6186-91
Arzumanyan, Alla; Friedman, Tiffany; Ng, Irene O L et al. (2011) Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 71:3701-8
Feitelson, Mark A; Reis, Helena M G P V; Tufan, N Lale et al. (2009) Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. Cancer Lett 286:69-79
Liu, Jie; Ahiekpor, Angela; Li, Li et al. (2009) Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer 125:1894-901
Cao, Wenjun; Sun, Bill; Feitelson, Mark A et al. (2009) Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int J Cancer 124:2886-92

Showing the most recent 10 out of 18 publications